MGX - Metagenomi Inc. Market Capitalization-to-Revenue Ratio

Symbol and logo of brand Metagenomi Therapeutics (MGX)

Metagenomi, Inc. (MGX) is currently focused on developing genome editing tools, which makes its revenues dependent on grants and partners. The fluctuation in the P/S ratio illustrates the market reaction to this risk. Meanwhile, AI-driven discovery of new nucleases creates a scientific standoff within the FDA, while colossal R&D expenditures form a powerful defensive barrier. The current 3.70 metric determines the status of the sales valuation parameter.

Metagenomi Inc. (MGX): Price-to-Revenue Ratio from 08/16/2024 to 11/15/2026

metagenomi.co (MGX) - metric breakdowns and financial figures

- price and consensus price forecast:
Fundamental company analysis:MGX (Metagenomi)
Original product of Metagenomi, Inc.

The P/S ratio determines the market value of a business relative to its actual cash flow from sales. By analyzing the P/S ratio of a company, an investor assesses the degree of overpayment for an asset through the ratio of market capitalization to revenue. This metric measures the commercial potential of an enterprise, excluding the impact of net income. For Metagenomi, Inc. (MGX), this reflects the market's confidence in the monetization of unique microbial tool libraries and new genome editing systems.

Competing companies

TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Market Cap to Revenue Ratio WGS|RARE (Ultragenyx Pharma) - P/S Multiple|P/S Multiple Beam Therapeutics Inc.|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Market Cap to Revenue Ratio|10x Genomics Inc - Market Cap to Revenue|NTLA (Intellia Therapeutics, Inc.) - Price-to-Sales Ratio|Stoke Corp - P/S Multiple|BLFS (BioLife) - Market Cap to Revenue Ratio|wavelifesciences.com (WVE) - Price-to-Revenue Ratio|MAZE - Price-to-Revenue Coefficient|SION (Sionna Therapeutics, Inc.) - P/S Multiple|Market Cap to Revenue Prime Medicine Corp (PRME)|P/S Multiple TSHA|P/S Multiple uniQure N.V. (QURE)|Price-to-Revenue Ratio MeiraGTx Holdings plc MGTX|RGNX: Market Cap to Revenue Ratio|Solid Biosciences Inc - P/S Multiple|OCGN - P/S Multiple|PACB: P/S Multiple|BNTC - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Design Therapeutics, Inc.|RCKT: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Korro Bio, Inc. KRRO|EDIT: Market Cap to Revenue Ratio|SLN - Price-to-Revenue Ratio|Price-to-Revenue Multiple ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Market Cap to Revenue|Sangamo Therapeutics Inc. (SGMO) - P/S Multiple|Price-to-Revenue Ratio Nautilus Bio|P/S Multiple Precision BioSciences Inc.|P/S Multiple GBIO|Boundless Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure, Inc.)|Price-to-Revenue Coefficient Imunon, Inc. (IMNN)|PHIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MBIO (mustangbio.com)|RNAZ: P/S Multiple|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio